 phase Clinical pharmacology pharmacokinetics Phase intravenous IV Pirarubicin patients good performance status refractory tumors Twenty-six minimal prior therapy good risk extensive prior therapy poor risk renal and/or hepatic dysfunction total courses doses evaluable Maximum dose good-risk patients poor-risk patients dose-limiting toxic effect transient noncumulative granulocytopenia Granulocyte nadir day range frequent toxic effects thrombocytopenia anemia nausea mild alopecia phlebitis mucositis Myelosuppression patients hepatic dysfunction Pharmacokinetic analyses patients Pirarubicin plasma alpha SE minutes minutes gamma hours area curve ng/ml hours volume distribution Vd total clearance ClT Adriamycinol doxorubicin adriamycinone tetrahydropyranyladriamycinol metabolites plasma amount doxorubicin equal total metabolites Urinary excretion Pirarubicin first hours equal Activity mesothelioma leiomyosarcoma basal cell carcinoma recommended starting dose Phase II trials IV weeks